Sun Pharma unit Taro recalls over 17k units of antifungal medication in US

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-12-26 07:00 GMT | Update On 2025-12-26 07:00 GMT

Sun Pharma unit Taro Pharmaceutical Industries is recalling more than 17,000 units of an antifungal medication in the US over manufacturing lapses, according to the US drug regulator.

In its latest Enforcement Report, the USFDA said Sun Pharma/Taro, based in Hawthorne, is recalling 17,664 units of Ciclopirox Shampoo, an antifungal treatment commonly prescribed for seborrheic dermatitis, a condition that causes dry, flaky and itchy skin.

The company is recalling the affected lot due to "Failed Impurity/Degradation specifications," the USFDA stated.

The company initiated the Class II nationwide recall on December 9 this year, PTI reported.

As per the USFDA, a Class-II recall is initiated when the use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences, or when the likelihood of serious adverse health outcomes is minimal.

Sun Pharmaceutical Industries completed the merger of Taro Pharmaceutical Industries with itself in a deal valued at USD 347.73 million last year.

After the merger, Taro is now a private company and wholly owned by Sun Pharma.

Sun Pharma has been the majority shareholder of Taro since 2010.

Primarily focused on dermatology, Taro produces a wide range of prescription and over-the-counter products.

Indian pharmaceutical companies supply a substantial proportion of drugs to US residents, with four out of ten of all prescriptions filled in the US in 2022 being supplied by Indian companies.

Read also: Taro Pharma now wholly owned by Sun Pharma

Article Source : With inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Sun Pharma unit Taro recalls over 17k units of antifungal medication in US

Similar News

Abbott's Vildagliptin SR Secures CDSCO Panel Nod on Post-Marketing Safety Data

Apollo Hospitals' Pharmacy, Healthtech Businesses Inch Closer to Demerger

Former IFS Officer Arrested in Spurious Medicines Racket in Puducherry

Patient dies in Pfizer Hemophilia drug study

Mirzapur pharmacy owner arrested after Rs 8.25 crore transactions surface in cough syrup probe

Strides Pharma Science arm New York facility gets 4 USFDA observations

Fortis Arm Challenges Rs 7 Cr GST Demand: Delhi HC to Decide Tax on Inpatient Medicines